AbbVie showcases breadth and depth of research in Crohn’s disease and ulcerative colitis at UEG Week 2023

AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (Skyrizi) and upadacitinib (Rinvoq in both Crohn’s disease (CD) and ulcerative colitis (UC)..

Key data presentations will include : i. Research highlighting endoscopic outcomes with Skyrizi and Rinvoq for CD: a. LB01: Risankizumab versus ustekinumab for patients with moderate to severe Crohn’s disease: results from the phase IIIb SEQUENCE study; Sunday, October 15, 17:00-17:12 CEST. b. OP100: Maintenance of clinical, endoscopic, and biomarker improvements with upadacitinib in patients with moderately to severely active Crohn’s disease: a post hoc analysis of the phase III U-ENDURE study; Monday, October 16, 15:06-15:18 CEST. ii. Insights on long-term use with Rinvoq for UC: a. PP0853: Achievement of long-term treatment goals with upadacitinib in patients with moderately to severely active ulcerative colitis: a post-hoc analysis of induction and maintenance phase III trials; Sunday, October 15, 10:00 CEST.b. OP149: Efficacy and safety of upadacitinib after 2 years of treatment in patients with moderately to severely active ulcerative colitis: interim results from the phase III open-label extension study (U-ACTIVATE); Tuesday, October 17, 08:54-09:06 CEST. iii. Primary efficacy and safety results from the Phase III induction study for risankizumab in UC: a. OP021: Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase III INSPIRE study; Sunday, October 15, 17:48-18:00 CEST.